Annual Reports

Financial Reports

Fiscal Year First Quarter Second Quarter Third Quarter Information Circular Financials & MD&A Annual Report


SEDAR View our filings as a publicly listed company in Canada (TSX).

EDGAR Our SEC filings as a publicly listed company in the United States (NASDAQ).

Analyst Coverage

Find out which analysts and institutions provide coverage of Oncolytics.

View Analyst Coverage

Latest News

December 04, 2014 Oncolytics Biotech® Inc. Collaborators Present REOLYSIN® and Checkpoint Inhibitor Combination Preclinical Data at AACR Tumor Immunology and Immunotherapy Conference
December 02, 2014 Oncolytics Biotech® Inc. Announces Filing for Orphan Drug Designation with the U.S. FDA for Pancreatic and Ovarian Cancers
November 18, 2014 Media Advisory - Oncolytics Biotech® Inc. to Participate in the Stifel 2014 Healthcare Conference
Sign up to receive e-mail updates *